Glide raises $4m for phase I trial of solid-dose teriparatide

Glide Technologies said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company.

Glide plans to use the funds to finish phase I trials this year for its solid dose formulation of a parathyroid hormone, teriparatide.

Get the full story at our sister site, Drug Delivery Business News.

The post Glide raises $4m for phase I trial of solid-dose teriparatide appeared first on MassDevice.

from MassDevice http://ift.tt/2jvWCzx